共 38 条
[1]
Chen W(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132
[2]
Zheng R(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[3]
Baade PD(2017)Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial Lancet Respir Med 5 707-716
[4]
Siegel RL(2013)Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 24 20-30
[5]
Miller KD(2015)BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer J Clin Oncol 33 2197-2204
[6]
Yang JJ(2010)Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lancet Oncol 11 733-740
[7]
Zhou C(2015)Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study Clin Cancer Res 21 1896-1903
[8]
Huang Y(2001)Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843-850
[9]
Soria JC(2010)Bevacizumab safety in patients with central nervous system metastases Clin Cancer Res 16 269-278
[10]
Mauguen A(2012)MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC Lung Cancer 76 373-379